Q-omics provides the consensus-scored CASC23 profile across patient tissues and cancer cell-line models. CASC23 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, CASC23 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, CASC23 RNA expression shows 6,581 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, THCA, and STAD as cancer lineages where CASC23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASC23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASC23 survival associations across molecular data types. CASC23 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASC23 RNA expression–survival associations across cancer types. High CASC23 expression shows unfavorable associations in ESCA, BLCA, KIRC, CESC and GBM, but favorable associations in HNSC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .029). Together, the overview and detailed table identify ESCA as the clearest survival context for CASC23 RNA expression.
This table summarizes CASC23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CASC23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASC23 shows lower tumor expression in THCA. The THCA box plot shows higher CASC23 RNA expression in normal versus tumor tissue (log2 FC = −0.005, t-test p = .040).
This table shows molecular features associated with CASC23 in patient tissues and cancer cell lines. In patient samples, CASC23 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
